More Images
The extensive quest to repurpose a cheap therapy for non-hospitalized COVID patients has once again fallen short, this time using a higher dose of fluvoxamine (Luvox), a selective serotonin reuptake inhibitor (SSRI). In the latest readout from the multi-platform ACTIV-6 trial, time to sustained recovery landed at an identical 10 days whether patients with mild to moderate cases received a 100-mg twice-daily dose of the SSRI or placebo, reported Susanna Naggie, MD, MHS, of Duke University School of Medicine in Durham, North Carolina, and colleagues in JAMA.

The new study, which involved a highly vaccinated patient population, adds to the mixed findings reported to date for fluvoxamine in COVID-19, with positive findings from the TOGETHER trials when used either alone or with inhaled budesonide, and negative results from the STOP COVID 2 and COVID-OUT trials. Prior results from ACTIV-6 testing a lower dose of fluvoxamine also failed to speed recovery time in outpatients.

Head over to MedPage Today to read more about it.